Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/rosuvastatin/telmisartan - Ildong Pharmaceutical

Next Previous
Drug Profile

Amlodipine/rosuvastatin/telmisartan - Ildong Pharmaceutical

Alternative Names: Amlodipine/telmisartan/rosuvastatin - Ildong Pharmaceutical; ID-TAR; Rosuvastatin/telmisartan/amlodipine- Ildong Pharmaceutical; TAR - Ildong Pharmaceutical; Telmisartan/amlodipine/rosuvastatin - Ildong Pharmaceutical; Telostop Plus

Latest Information Update: 10 Sep 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ildong Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Cytochrome P-450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 10 Sep 2018 Chemical structure information added
  • 31 Aug 2018 IlDong Pharmaceutical plans a phase IV trial for Hypertension and Hyperlipidemia in South Korea (NCT03648801)
  • 01 Aug 2018 Launched for Hyperlipidaemia in South Korea (PO) (IlDong Pharmaceutical pipeline, August 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top